Brendan P. Eckelman net worth and biography

Brendan Eckelman Biography and Net Worth

Insider of Inhibrx

Dr. Eckelman co-founded Inhibrx in April 2010 and currently serves as our Chief Scientific Officer and Executive Vice President of Corporate Strategy. From August 2015 to November 2018, he served as our Chief Operating Officer and Vice President of Biotherapeutics. From 2010 until August 2015, Dr. Eckelman served as our Vice President of Scientific Operations. He has served as a member of our board of directors since April 2018.

Dr. Eckelman is the head of our research team, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporate strategy and operations. Prior to co-founding Inhibrx, Dr. Eckelman was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received a Ph.D. in Molecular Pathology from the University of California, San Diego (UCSD), School of Medicine. Dr. Eckelman received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.

What is Brendan P. Eckelman's net worth?: The estimated net worth of Brendan P. Eckelman is at least $71.89 million as of February 1st, 2023. Dr. Eckelman owns 2,086,803 shares of Inhibrx stock worth more than $71,890,363 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Eckelman may own. Additionally, Dr. Eckelman receives a salary of $769,250.00 as Insider at Inhibrx. Learn More about Brendan P. Eckelman's net worth.
How old is Brendan P. Eckelman?: Dr. Eckelman is currently 44 years old. There are 3 older executives and no younger executives at Inhibrx. The oldest executive at Inhibrx is Mr. Mark Paul Lappe, Founder, Chairman, President & CEO, who is 56 years old. Learn More on Brendan P. Eckelman's age.
What is Brendan P. Eckelman's salary?: As the Insider of Inhibrx, Inc., Dr. Eckelman earns $769,250.00 per year. The highest earning executive at Inhibrx is Mr. Mark Paul Lappe, Founder, Chairman, President & CEO, who commands a salary of $1,100,000.00 per year. Learn More on Brendan P. Eckelman's salary.
How do I contact Brendan P. Eckelman?: The corporate mailing address for Dr. Eckelman and other Inhibrx executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Brendan P. Eckelman's contact information.
Has Brendan P. Eckelman been buying or selling shares of Inhibrx?: Brendan P. Eckelman has not been actively trading shares of Inhibrx in the last ninety days. Most recently, Brendan P. Eckelman sold 28,750 shares of the business's stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $24.73, for a transaction totalling $710,987.50. Following the completion of the sale, the insider now directly owns 2,086,803 shares of the company's stock, valued at $51,606,638.19. Learn More on Brendan P. Eckelman's trading history.
Who are Inhibrx's active insiders?: Inhibrx's insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), and Mark Lappe (Founder). Learn More on Inhibrx's active insiders.
Are insiders buying or selling shares of Inhibrx?: During the last twelve months, Inhibrx insiders bought shares 1 times. They purchased a total of 511,627 shares worth more than $9,899,982.45. The most recent insider tranaction occured on August, 28th when Major Shareholder Global Investors Lp Viking bought 511,627 shares worth more than $9,899,982.45. Insiders at Inhibrx own 22.2% of the company. Learn More about insider trades at Inhibrx.
Information on this page was last updated on 8/28/2023.

Brendan P. Eckelman Insider Trading History at Inhibrx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2023	Sell	28,750	$24.73	$710,987.50	2,086,803
1/3/2023	Sell	32,895	$23.77	$781,914.15	2,122,658
12/6/2022	Sell	40,000	$27.22	$1,088,800.00	2,155,553
11/1/2022	Sell	40,000	$33.51	$1,340,400.00	2,195,553
10/4/2022	Sell	40,000	$27.82	$1,112,800.00	2,235,553
8/2/2022	Sell	24,500	$17.70	$433,650.00	2,491,053
7/7/2022	Sell	40,000	$17.17	$686,800.00	2,515,553
4/5/2022	Sell	400	$25.04	$10,016.00
3/24/2021	Sell	17,000	$19.02	$323,340.00
2/16/2021	Sell	17,000	$25.90	$440,300.00	234,709

Brendan P. Eckelman Buying and Selling Activity at Inhibrx

Inhibrx Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Today's Range

Now: $34.45

$34.45

$34.83

50 Day Range

MA: $35.92

$34.45

$39.56

2 Week Range

Now: $34.45

$14.31

$39.79

Volume

415,786 shs

Average Volume

698,410 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.91

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Brendan Eckelman Biography and Net Worth

What is Brendan P. Eckelman's net worth?

How old is Brendan P. Eckelman?

What is Brendan P. Eckelman's salary?

How do I contact Brendan P. Eckelman?

Has Brendan P. Eckelman been buying or selling shares of Inhibrx?

Who are Inhibrx's active insiders?

Are insiders buying or selling shares of Inhibrx?